Januvia approved as add-on to insulin treatment

Januvia (sitagliptin) can now be prescribed as an add-on to insulin (with or without metformin) for patients with type II diabetes in whom diet and exercise, plus a stable dose of insulin, do not provide adequate glycaemic control. In a 24-week study in 305 patients, addition of sitagliptin to insulin significantly improved glycaemic parameters compared with placebo, with no major effect on body weight. When Januvia is combined with insulin, reduction of the insulin dose may be appropriate to reduce the risk of hypoglycaemia.

View Januvia drug record

Further information: MSD

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from intelog

Drug shortages - live tracker

Drug shortages - live tracker

Added: ranitidine.
Use our constantly updated...

intelog Learning's Espresso CPD helps GPs to top up credits for appraisal

intelog Learning's Espresso CPD helps GPs to top up credits for appraisal

Bite-size Espresso learning can help you top up your...

Monitor high-risk statin patients for osteoporosis, say researchers

Monitor high-risk statin patients for osteoporosis, say researchers

Patients taking high-dose statins who are at increased...

Oral Iron Supplements for Iron-Deficiency States

Oral Iron Supplements for Iron-Deficiency States

Formulations, strengths, doses and costs of iron supplements.